tozuleristide

Drug Overview

• Generic Name: tozuleristide
• US Brand Names: BLZ-100, Tumor Paint
• Drug Class: Fluorescent Tumor Marking Agent / Peptide-Fluorophore Conjugate
• Route of Administration: Intravenous (IV) Injection
• FDA Approval Status: Investigational (Currently in Phase 1, 2, and 3 clinical trials; not yet FDA-approved for standard public use).

Tozuleristide, often known by its brand name Tumor Paint, is a highly advanced “Smart Drug” and targeted imaging agent. It is not a traditional medicine meant to kill cancer cells on its own. Instead, it acts like a glowing spotlight that helps surgeons see exactly where a tumor is during an operation. By making cancer cells glow, it helps doctors remove the whole tumor while keeping the surrounding healthy tissue safe.

What Is It and How Does It Work? (Mechanism of Action)

To understand tozuleristide, it helps to look at its two main parts. It is a unique combination of a targeting protein and a glowing dye.

1. The Scout (Chlorotoxin): The first part is a tiny protein called chlorotoxin. Interestingly, this protein is a synthetic version of a substance found naturally in the venom of the deathstalker scorpion. This protein acts like a heat-seeking missile. After it enters the blood, it travels through the body looking for specific doorways, called Annexin A2 and MMP-2 proteins, that are heavily clustered on the outside of cancer cells.
2. The Glowing Tag (Indocyanine Green): The second part is a safe, fluorescent dye called indocyanine green (ICG). This dye is permanently attached to the scorpion protein.

When tozuleristide is injected into the patient’s vein, it flows through the body and sticks tightly to the cancer cells. The tumor cells then pull the drug inside. During surgery, the doctor uses a special near-infrared (NIR) camera system. When this invisible camera light hits the tumor, the dye lights up, making the cancer cells glow brightly. This allows the surgeon to see the exact edges of the tumor, making tozuleristide a powerful Targeted Therapy tool for precision surgery.

FDA-Approved Clinical Indications

Because tozuleristide is an investigational drug, it does not currently have official FDA-approved uses for routine medical practice. However, it is being actively studied in advanced clinical trials for the following areas:

Oncological Uses (In Clinical Trials):

• Brain and Spinal Cord Tumors: Used in both adults and children for high-grade and low-grade gliomas, ependymomas, and medulloblastomas.
• Skin Cancer: Used to clearly find the edges of basal cell carcinomas and melanomas.
• Breast Cancer: Used to guide the removal of breast tumors.
• Head and Neck Cancers: Used to spot oral cavity squamous cell cancer and abnormal precancerous cells during surgery.

Non-oncological Uses:

• There are currently no non-oncological uses being studied. The drug’s sole focus is on improving cancer surgery.

Dosage and Administration Protocols

Tozuleristide is given as a single dose before a patient goes into surgery. Because it is a surgical imaging agent, it is not a drug that a patient takes every day at home.

Dose Adjustments:

Because it is an investigational drug, patients must have standard, healthy liver and kidney function to participate in trials. For example, blood tests must show normal bilirubin and liver enzymes. There are no specific dose adjustments for severe liver or kidney failure yet, as those patients are generally not included in early trials for safety reasons.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) show that tozuleristide is highly effective at finding and highlighting cancer.

• Brain Tumor Success: In pediatric brain cancer trials, 80% of children who received the drug had tumors that successfully lit up under the camera. In adult studies, the drug accurately labeled high-grade brain tumors 100% of the time when given at doses of 9 mg or higher.
• Skin Cancer Success: In a first-in-human skin cancer study, the drug successfully made 4 out of 5 basal cell carcinomas and 4 out of 4 melanomas glow, matching exactly with the cancer found by pathologists.
• Improving Patient Outcomes: While this drug does not cure cancer directly, removing the tumor completely is the most important step for survival in brain cancer. Research shows that removing more than 98% of a glioblastoma (a fast-growing brain tumor) can increase average survival from 52 weeks to 86 weeks. Tozuleristide gives surgeons the exact map they need to reach that 98% goal safely without harming healthy brain tissue.

Safety Profile and Side Effects

Tozuleristide has proven to be very safe in early human trials. Because it is given just once and in very small amounts, it does not cause the severe side effects associated with standard chemotherapy. During testing, researchers did not even reach a “Maximum Tolerated Dose,” meaning even the highest tested doses (30 mg) were safe.

Black Box Warning: There is no FDA Black Box Warning for this investigational drug.

Common Side Effects (>10%)

• Headache: Mild head pain following the injection.
• Nausea: A slight upset stomach or feeling of sickness.
• Injection Site Reactions: Mild redness, pain, or bruising where the IV needle was placed.

Serious Adverse Events

• To date, no serious adverse events, severe allergic reactions, or deaths have been linked directly to the tozuleristide drug in Phase 1 clinical trials.

Management Strategies

• If a headache or nausea occurs, the medical team can provide standard, over-the-counter pain relievers or anti-nausea medicine.
• Patients are monitored closely in the hospital or clinic after the injection to ensure they remain comfortable before their surgery.

Connection to Stem Cell and Regenerative Medicine

While tozuleristide is primarily a surgical tool and not a direct stem cell therapy, it plays an important supporting role in regenerative and advanced cellular medicine. New treatments like CAR-T cell therapy (where a patient’s immune cells are programmed to fight brain tumors) work best when the main tumor bulk is completely removed. By using tozuleristide to safely cut out the cancer while perfectly preserving the healthy brain tissue around it, doctors create a much healthier environment for future stem cell or immune therapies to work. Preserving healthy nerve pathways is the ultimate goal of regenerative neurology, and this “smart dye” makes that precision possible.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Imaging Scans: Standard MRI or CT scans must be done first to locate the tumors.
• Blood Tests: Standard liver function tests to ensure the body can safely process the dye.
• Pregnancy Test: A negative blood pregnancy test is strictly required for women of childbearing age, as the drug’s effect on an unborn baby is not yet known.

Precautions During Treatment:

• The drug is given through an IV in a pre-surgery waiting area or a clinic a day prior.
• You will not feel the drug “glowing” inside you. The glow is completely invisible to the naked eye and can only be seen with the surgeon’s special camera in the operating room.

“Do’s and Don’ts” List:

• DO follow all rules about fasting (not eating or drinking) before your surgery.
• DO tell your doctor about all other medicines and supplements you are taking.
• DON’T participate in these trials if you are pregnant or breastfeeding.
• DON’T worry if your surgery time is delayed by a few hours. The dye stays safely trapped in the tumor for up to 36 hours, so the surgeon will still be able to see it clearly.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Tozuleristide is an investigational diagnostic agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.